Like most U.S. hospitals, Cincinnati Children's is affected by the IV fluid shortage caused by damage to Baxter International's North Carolina production facility during Hurricane Helene. Our teams will continue to watch this situation and will provide any updates as needed.
Atmar RL, Bernstein DI, Lyon GM, Treanor JJ, Al-Ibrahim MS, Graham DY, Vinjé J, Jiang X, Gregoricus N, Frenck RW, Moe CL, Chen WH, Ferreira J, Barrett J, Opekun AR, Estes MK, Borkowski A, Baehner F, Goodwin R, Edmonds A, Mendelman PM. Serological Correlates of Protection against a GII.4 Norovirus. Clin Vaccine Immunol. 2015 Aug;22(8):923-9.
Currently the correlate of protection against Norovirus is unclear. Having a good correlate will enhance our ability to determine the predicted efficacy of a vaccine candidate. This study furthers our understanding of protection against norovirus and may lead to improved ability to evaluate candidate vaccines.
Cytomegalovirus (CMV) continues to be a significant cause of morbidity in neonates. Developing a vaccine to protect mothers against CMV could significantly improve the health of mothers and their offspring. This trial reports the experience of a large trial to evaluate the protective effect of a candidate vaccine against CMV.
Cholera remains a common cause of severe diarrhea in many parts of the world resulting in an estimated 1.5 million cases annually and approximately 100,000 deaths/year. At the present, there is no vaccine licensed against cholera in the US. This trial was instrumental in the vaccine receiving approval from the FDA for use in travelers
Non-adherence to medical recommendations has shown to be a major cause for failure of the graft. This project examined potential barriers to adherence and ways to improve adherence.
In the US, currently licensed rotavirus (RV) vaccines have resulted in a markedly reduction in RV disease. However, the vaccines have not been as effective in parts of the developing world. This study provides us information to move us closer to testing in children of a new candidate vaccine against RV.